AR109199A1 - Composición y uso de un péptido - Google Patents

Composición y uso de un péptido

Info

Publication number
AR109199A1
AR109199A1 ARP170102151A ARP170102151A AR109199A1 AR 109199 A1 AR109199 A1 AR 109199A1 AR P170102151 A ARP170102151 A AR P170102151A AR P170102151 A ARP170102151 A AR P170102151A AR 109199 A1 AR109199 A1 AR 109199A1
Authority
AR
Argentina
Prior art keywords
peptide
composition
seq
treat
neglected diseases
Prior art date
Application number
ARP170102151A
Other languages
English (en)
Inventor
De Araujo Christiane Bezerra
Barbosa Elias Sabbaga Maria Carolina Quartim
Original Assignee
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Butantan filed Critical Fund Butantan
Publication of AR109199A1 publication Critical patent/AR109199A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composición que comprende un péptido según se define en SEQ ID Nº 1, 3, 4 ó 5 y un vehículo farmacéuticamente aceptable. Uso de un péptido según se define en SEQ ID Nº 1, 3, 4 ó 5 en la manufactura de una composición farmacéutica para tratar enfermedades desatendidas. Método para tratar enfermedades desatendidas. Reivindicación 5: Uso según la reivindicación 4, caracterizado porque las enfermedades desatendidas se seleccionan entre la enfermedad de Chagas, la enfermedad del sueño y la leishmaniasis.
ARP170102151A 2016-07-29 2017-07-28 Composición y uso de un péptido AR109199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102016017666-2A BR102016017666A2 (pt) 2016-07-29 2016-07-29 Composição, e, uso de um peptídeo

Publications (1)

Publication Number Publication Date
AR109199A1 true AR109199A1 (es) 2018-11-07

Family

ID=59626401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102151A AR109199A1 (es) 2016-07-29 2017-07-28 Composición y uso de un péptido

Country Status (6)

Country Link
AR (1) AR109199A1 (es)
BR (1) BR102016017666A2 (es)
CL (1) CL2019000236A1 (es)
CO (1) CO2019000942A2 (es)
MX (1) MX2019001320A (es)
WO (1) WO2018018121A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909254A (zh) * 2019-05-10 2020-11-10 国家纳米科学中心 抑制肿瘤活性的多肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102014000521B1 (pt) 2014-01-09 2021-05-25 Proteimax Biotecnologia Ltda peptídeo, uso, composição farmacêutica, método in vitro de inibição ou de identificação de células em divisão

Also Published As

Publication number Publication date
BR102016017666A2 (pt) 2018-02-14
WO2018018121A1 (en) 2018-02-01
MX2019001320A (es) 2019-09-19
CL2019000236A1 (es) 2019-06-07
CO2019000942A2 (es) 2019-02-08

Similar Documents

Publication Publication Date Title
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
MX2021004191A (es) Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CL2016003293A1 (es) Inhibidores de mnk y método relacionado al mismo
MX2021002321A (es) Nuevos metodos.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
MX2021002322A (es) Nuevos metodos.
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
EA201791525A2 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
AR109199A1 (es) Composición y uso de un péptido
CO2017012397A2 (es) Fragmento de anticuerpo fab anti-ngf humano
UY37065A (es) Método de purificación
ZA202006986B (en) Dantrolene formulations and methods of their use
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
CL2017003465A1 (es) Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria.